Core B: Bioenergetics Mitochondrial dysfunction has long been a consistent observation in Parkinson's disease (PD). To understand the consequences of PD disease causing genetic mutations on the function of mitochondria the Bioenergetics Core B will provide the following analyses to the three projects in this program including: Measuring rates of respiration, oxygen consumption and ATP generation, Measuring calcium dynamics, Measuring reactive oxygen and reactive nitrogen species, measuring the activity of the electron transport chain enzymes and metabolic enzymes, and Measuring plasma versus mitochondria! membrane potential and mitochondria! membrane permeability. The Bioenergetics Core B is a shared resource of the Program. It will measure mitochondria! function, membrane permeability and membrane potential in the presence of AIMP2 and characterize mitochondria! enzymes, oxygen consumption and ATP concentrations in the conditional AIMP2 transgenic mice for Project 1. For Project 2 the Core will measure electron transport chain enzymes and metabolic enzymes and reactive oxygen and reactive nitrogen species in the various models of alpha-synuclein mediated neuronal injury. For Project 3 all measures of mitochondria! function will be conducted to characterize the LRRK2 knockout and LRRK2 transgenic mice. Thus this Core will play a central and integrated role in the investigations in the pathogenesis of PD of this Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS038377-11
Application #
7664246
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2009-09-30
Budget End
2010-07-31
Support Year
11
Fiscal Year
2009
Total Cost
$139,618
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Dawson, Ted M; Golde, Todd E; Lagier-Tourenne, Clotilde (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370-1379
Lee, Saebom; Kim, Sangjune; Park, Yong Joo et al. (2018) The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Hum Mol Genet 27:2344-2356
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Yun, Seung Pil; Kam, Tae-In; Panicker, Nikhil et al. (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24:931-938
Hinkle, Jared Thomas; Perepezko, Kate; Bakker, Catherine C et al. (2018) Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Mov Disord Clin Pract 5:31-38
Kam, Tae-In; Mao, Xiaobo; Park, Hyejin et al. (2018) Poly(ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson's disease. Science 362:
Sathe, Gajanan; Na, Chan Hyun; Renuse, Santosh et al. (2018) Phosphotyrosine profiling of human cerebrospinal fluid. Clin Proteomics 15:29
Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74
Hinkle, Jared T; Perepezko, Kate; Bakker, Catherine C et al. (2018) Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 33:e131-e139
Hinkle, Jared T; Perepezko, Kate; Mills, Kelly A et al. (2018) Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord 55:8-14

Showing the most recent 10 out of 250 publications